NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kulkarni - President of Lab Operations and CSO Conference Call Participants Alex Nowak - Craig-Hallam Capital Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Puneet Souda - SVB Securities Andrew Cooper - Raymond James Mark Massaro - B ...

| --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | August 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lynn Tetrault ??? Interim CEO Charlie Eidson ??? Director of Investor Relations Bill Bonello ??? Chief Financial Officer Chris Smith ??? Incoming Chief Executive Officer David Sholehvar ??? President, Clinical Division Vishal Sikri ??? President, Pharma Services Division and President-Inivata Conference Call Participants Brian Weinstein ??? William Blair Alex Nowak ??? Craig-Hallum David Westenberg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Financial Officer Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor Relations Shashi Kulkarni - Chief Scientific Officer David Sholehvar - Clinical Division President Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Andrew Coope ...

| --- | --- | --- | --- | --- | --- | |-----------------------|-------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investor Presentation | NeoGenomics | | | | | | April 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy s ...

Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35756 For the transition period from _________ to __________ 9490 NeoGenomics Way, Fort Myers, FL 33912 (A ...

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | February 2022 | | | | | Forward‐Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of ...

NeoGenomics Inc. (NASDAQ:NEO) Q4 2021 Earnings Conference Call February 23, 2022 8:30 AM ET Company Participants Mark Mallon - Chief Executive Officer William Bonello - Chief Financial Officer Clive Morris - President, Inivata George Cardoza - President, Chief Operating Officer Gina Waller - President, Pharma Services Clynt Taylor - President, Informatics Charlie Eidson - Director, Investor Relations Conference Call Participants Brian Weinstein - William Blair Mark Massaro - BTIG Alex Nowak - Craig Hallum P ...